Biotech vs. Shorts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KewlHand who wrote (344)	1/31/2000 12:53:00 AM
From: Miljenko Zuanic	of 427

<<Addressing an orphan condition for the NDA was a smart move on the companies part, it gives a much higher chance of getting FDA approval and brings the drug to market sooner. BUT!....>> But, You are wrong. Orphan status doesn't increase chance for approval. Only give developer 7 years marketing exclusivity, and it is reward to those who develop drug where big guys doesn't want to waste time. Also, I will like that Aptosyn did have AC meeting as we will learn more about drug and FDA concern (like for IMNX drug). <<We already know from doctors posting on the RagingBull thread that it WILL be used off label, ..>> Doesn't they have anything better to do than chat online? Hospitals are full of patients which are thirsty for few nice words! Good luck, anyway. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next